Sarepta Therapeutics, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US8036071004
USD
21.13
-0.66 (-3.03%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationQuarterly Results
Results Snapshot
YoYQoQ
Figures in Million
Consolidate Quarterly Results
Sep'25
Jun'25
Mar'25
Dec'24
Sep'24
Jun'24
Mar'24
Net Sales
399.36
611.09
744.86
658.41
467.17
362.93
413.46
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
399.36
611.09
744.86
658.41
467.17
362.93
413.46
Raw Material Cost
169.22
163.40
147.54
142.76
101.50
53.26
59.30
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
24.44
58.86
64.62
66.01
57.30
57.21
57.81
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
7.57
5.23
4.50
4.47
4.92
4.83
4.17
Selling and Distribution Expenses
74.12
127.72
124.25
161.38
125.66
136.66
124.91
Other Expenses
18.69
14.03
70.43
12.21
15.56
11.17
13.24
Total Expenditure (Excl Depreciation)
462.24
495.51
1,045.24
496.73
444.98
363.63
378.56
Operating Profit (PBDIT) excl Other Income
-62.9
115.60000000000001
-300.4
161.70000000000002
22.200000000000003
-0.7000000000000001
34.900000000000006
Other Income
7.68
6.57
12.10
13.81
15.19
19.11
20.81
Operating Profit (PBDIT)
-33.38
137.01
-274.38
189.82
51.52
31.14
68.41
Interest
7.57
5.23
4.50
4.47
4.92
4.83
4.17
Exceptional Items
-131.28
36.72
-90.73
0.73
1.53
0.00
-10.10
Gross Profit (PBDT)
230.13
447.69
597.31
515.65
365.68
309.67
354.16
Depreciation
21.82
14.86
13.91
14.33
14.13
12.73
12.70
Profit Before Tax
-194.05
153.64
-383.52
171.74
34.01
13.58
41.45
Tax
-14.10
-43.25
63.99
12.69
0.40
7.12
5.33
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
-179.95
196.89
-447.51
159.05
33.61
6.46
36.12
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
-179.95
196.89
-447.51
159.05
33.61
6.46
36.12
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
-179.95
196.89
-447.51
159.05
33.61
6.46
36.12
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Reserves
1,320.12
1,357.38
1,142.72
1,527.74
1,221.07
1,077.07
961.19
Earnings per share (EPS)
-1.8
1.89
-4.6
1.61
0.34
0.07
0.36
Diluted Earnings per share
-1.8
1.89
-4.6
1.61
0.34
0.07
0.36
Operating Profit Margin (Excl OI)
-15.75%
18.91%
-40.33%
24.56%
4.75%
-0.19%
8.44%
Gross Profit Margin
-43.13%
27.57%
-49.62%
28.26%
10.3%
7.25%
13.1%
PAT Margin
-45.06%
32.22%
-60.08%
24.16%
7.19%
1.78%
8.74%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - YoY
stock-summary

Net Sales

YoY Growth in quarter ended Sep 2025 is -14.51% vs 40.81% in Sep 2024

stock-summary

Consolidate Net Profit

YoY Growth in quarter ended Sep 2025 is -635.42% vs 182.15% in Sep 2024

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in quarter ended Sep 2025 is -213.22% vs 695.08% in Sep 2024

stock-summary

Interest

YoY Growth in quarter ended Sep 2025 is 55.10% vs -5.77% in Sep 2024

stock-summary

Operating Profit Margin (Excl OI)

YoY Growth in quarter ended Sep 2025 has fallen from Sep 2024

Compare Quarterly Results Of Sarepta Therapeutics, Inc. With
Markets Mojo
Figures in Million
Consolidate Quarterly Results
Markets Mojo
Markets Mojo
Change(USD)
Change(%)
Net Sales
399.36
578.66
-179.30
-30.99%
Other Operating Income
0.00
0.00
0.00
Total Operating income
399.36
578.66
-179.30
-30.99%
Raw Material Cost
169.22
0.00
169.22
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
24.44
0.00
24.44
Power Cost
0
0
0.00
Manufacturing Expenses
7.57
68.67
-61.10
-88.98%
Selling and Distribution Expenses
74.12
272.30
-198.18
-72.78%
Other Expenses
18.69
23.18
-4.49
-19.37%
Total Expenditure (Excl Depreciation)
462.24
572.80
-110.56
-19.30%
Operating Profit (PBDIT) excl Other Income
-62.88
5.86
-68.74
-1,173.04%
Other Income
7.68
9.48
-1.80
-18.99%
Operating Profit (PBDIT)
-33.38
219.28
-252.66
-115.22%
Interest
7.57
68.67
-61.10
-88.98%
Exceptional Items
-131.28
-59.97
-71.31
-118.91%
Gross Profit (PBDT)
230.13
0.00
230.13
Depreciation
21.82
0.00
21.82
Profit Before Tax
-194.05
90.64
-284.69
-314.09%
Tax
-14.10
0.00
-14.10
Provisions and contingencies
0
0
0.00
Profit After Tax
-179.95
30.18
-210.13
-696.26%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
-179.95
30.18
-210.13
-696.26%
Share in Profit of Associates
0
0
0.00
Minority Interest
0.00
60.46
-60.46
-100.00%
Other related items
0.00
0.00
0.00
Consolidated Net Profit
-179.95
90.64
-270.59
-298.53%
Equity Capital
0
0
0.00
Face Value
0.00
0.00
0.00
Reserves
1,320.12
6,347.91
-5,027.79
-79.20%
Earnings per share (EPS)
-1.80
0.07
-1.87
-2,671.43%
Diluted Earnings per share
-1.80
0.07
-1.87
-2,671.43%
Operating Profit Margin (Excl OI)
-15.75%
36.26%
0.00
-52.01%
Gross Profit Margin
-43.13%
15.66%
0.00
-58.79%
PAT Margin
-45.06%
5.21%
0.00
-50.27%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Quarterly - Net Sales
Net Sales 39.94 Million
in Sep 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Sep 2025 is -34.64% vs -17.96% in Jun 2025

stock-summary

YoY Growth in quarter ended Sep 2025 is -14.51% vs 40.81% in Sep 2024

Quarterly - Consolidate Net Profit
Consolidate Net Profit -17.99 Million
in Sep 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Sep 2025 is -191.37% vs 144.00% in Jun 2025

stock-summary

YoY Growth in quarter ended Sep 2025 is -635.42% vs 182.15% in Sep 2024

Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) -4.11 Million
in Sep 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Sep 2025 is -131.52% vs 145.51% in Jun 2025

stock-summary

YoY Growth in quarter ended Sep 2025 is -213.22% vs 695.08% in Sep 2024

Quarterly - Interest
Interest 0.76 Million
in Sep 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Sep 2025 is 46.15% vs 15.56% in Jun 2025

stock-summary

YoY Growth in quarter ended Sep 2025 is 55.10% vs -5.77% in Sep 2024

Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) -15.75%
in Sep 2025

Figures in %
stock-summary

QoQ Growth in quarter ended Sep 2025 has fallen from Jun 2025

stock-summary

YoY Growth in quarter ended Sep 2025 has fallen from Sep 2024